Senseonics See Few Barriers To Adoption For Their Implantable CGM

GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.

paper airplanes
• Source: Shutterstock

The diabetes devices sector has been steadily marching along in recent years with near-constant product releases and debuts of data.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

Abbott Embeds Libre Glucose Data In Epic EHR, Expanding Digital Health Footprint

 
• By 

Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.

Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move

 
• By 

Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By 

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.

Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

 
• By 

Only 14% of people with type 2 diabetes use continuous glucose monitors, although 93% of users report a positive impact on their health. Dexcom is ramping up efforts to close this adoption gap.

More from Device Area